Acadia – $230 Million Follow-On

San Diego – August 24, 2016 – Cooley advised Acadia Pharmaceuticals on its follow-on offering of 6,969,696 shares of common stock for gross proceeds of $230 million.

Acadia, which trades on The NASDAQ Global Select Market as "ACAD," is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. Its portfolio includes NUPLAZID (pimavanserin), which was approved by the FDA on April 29 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis and is the only drug approved in the US for this condition.

Cooley advised ACADIA on its 2004 IPO and has since represented the company in numerous follow-on offerings.

The Cooley corporate and securities team advising Acadia included Sean Clayton, Asa Henin, Carlos Ramirez, John Ross and Kay Chandler.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.